Clinical Trials Logo
  1. Home
  2. PCNSL
  3. NCT05167630

Prognosis Factors in Patients With Primary Central Nervous System Lymphoma

PCNSL Clinical Trial

Official title:
Prognosis Factors in Patients With Primary Central Nervous System Lymphoma

Clinical Trial Summary

Primary central nervous system lymphoma (PCNSL) is a rare extranodal non-hodgkin's lymphoma confined to the central nervous system. It accounts for about 4% of all intracranial tumors and 4% to 6% of all non-Hodgkin's lymphomas . Among them, the most common type is diffuse large B cell lymphoma (DLBCL), accounting for about 95% of all cases. High dose methotrexate (HD-MTX) based chemotherapy can improve the prognosis of patients, but only 30% to 40% of patients can achieve sustained remission, and the overall prognosis is very poor[4, 6]. Currently, the International Extranodal Lymphoma Study Group (IESLG) prognostic scoring system and the Memorial Sloan Kettering Cancer Center (MSKCC) prognostic index are widely used to evaluate the prognosis in patients with PCNSL. However, IESLG model has some limitations such as the relatively small number of patients and short follow-up period. MSKCC model may have an inherent selection bias because retrospective data were collected from a single large institution. Therefore, there is a urgent need to identify novel indicators for prognosis evaluation and risk stratification in PCNSL patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05167630
Study type Observational
Source Zhengzhou University
Contact Mingzhi Zhang, Doctor
Phone +8637166295561
Email mingzhi_zhang1@163.com
Status Recruiting
Phase
Start date September 1, 2013
Completion date December 15, 2021
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04514393 - Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma Phase 2
Recruiting NCT04481815 - Rituximab Plus Methotrexate With or Without Lenalidomide in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Phase 2
Active, not recruiting NCT04438044 - A Study to Evaluate ICP-022 in Patients With R/R PCNSL and SCNSL Phase 2
Recruiting NCT05896007 - Zanubrutinib Combined With Rituximab and Chemotherapy for Newly-Diagnosed PCNSLBCL Patients Intolerant to HSCT Phase 2
Active, not recruiting NCT03392714 - Bendamustine-based Combination Therapy for PCNSL Phase 2
Not yet recruiting NCT05021770 - Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma Phase 1/Phase 2
Recruiting NCT05782374 - Real World Data on Ibrutinib Use in PCNSL Rel/Ref